Precigen, Inc. (PGEN)Healthcare | Biotechnology | Germantown, United States | NasdaqGS
7.39 USD
-0.09
(-1.270%) ⇩
(Oct. 14, 2026, 3:16 p.m.
EDT)
|
Hot Take ↕ | Oct. 10, 2026, 5:16 a.m. EDT
The immediate narrative is a classic biotech turnaround play. While the fundamentals are currently distressed—negative earnings, high debt-to-equity, and a massive 89% drawdown over the last nine years—the market is pricing in a significant recovery. The recent price action shows resilience, bouncing off the $5 level and trading near the 200-day average, which supports a 'slight upside lean' for the near term. However, the long-term outlook remains neutral due to the lack of sustained profitability and the sheer magnitude of the historical decline; the business has not yet proven it can generate the consistent cash flows required to justify a premium valuation. The options market confirms this tension: traders are hedging downside risks while simultaneously betting on a sharp move higher, likely anticipating the upcoming Q2 results and the FDA news mentioned in headlines. Until the company demonstrates a path to profitability or a blockbuster product launch, this remains a speculative vehicle rather than a core holding. |
| Model | MAE |
|---|---|
| AutoARIMA ✓ | 0.157233 |
| AutoTheta | 0.190793 |
| AutoETS | 0.244426 |
| MSTL | 0.259067 |
Forecast horizon: 45 days | Selected: AutoARIMA
| Forecast Reliability | |
|---|---|
| Score | 35% |
| H-stat | 1.31 |
| Ljung-Box p | 0.000 |
| Jarque-Bera p | 0.092 |
| Excess Kurtosis | 0.70 |
| Attribute | Value |
|---|---|
| Sector | Healthcare |
| Debt to Equity Ratio | 225.686 |
| Revenue per Share | 0.25 |
| Market Cap | 2,632,833,536 |
| Forward P/E | -33.57 |
| Beta | 0.92 |
| Profit Margins | -183.98% |
| Website | https://precigen.com |
As of Oct. 10, 2026, 5:16 a.m. EDT: Speculators are positioning for a volatile rebound rather than a steady grind. In the near term (Oct 2026), there is heavy put volume at deep out-of-the-money strikes ($3.00), suggesting a hedge against a crash to previous lows, while call interest clusters around the $10.00 strike, implying a target for a 30% rally. For the intermediate horizon (Jan 2027), the skew flips dramatically: massive open interest in calls at $10.00 and $13.00 indicates a bullish thesis that the company can recover and exceed current levels, whereas put activity is minimal. This asymmetry suggests traders believe the current dip is a buying opportunity driven by potential catalysts like the mentioned FDA approval.
| Attribute | Value |
|---|---|
| 52 Week Change | 1.1189802 |
| Address1 | 20,374 Seneca Meadows Parkway |
| All Time High | 68.83053 |
| All Time Low | 0.65 |
| Ask | 8.63 |
| Ask Size | 1 |
| Audit Risk | 5 |
| Average Daily Volume10 Day | 5,395,810 |
| Average Daily Volume3 Month | 5,007,028 |
| Average Volume | 5,007,028 |
| Average Volume10Days | 5,395,810 |
| Beta | 0.919 |
| Bid | 6.51 |
| Bid Size | 1 |
| Board Risk | 7 |
| Book Value | 0.122 |
| City | Germantown |
| Compensation As Of Epoch Date | 1,767,139,200 |
| Compensation Risk | 8 |
| Country | United States |
| Crypto Tradeable | 0 |
| Currency | USD |
| Current Price | 7.385 |
| Current Ratio | 4.578 |
| Custom Price Alert Confidence | HIGH |
| Date Short Interest | 1,790,726,400 |
| Day High | 7.695 |
| Day Low | 7.3802 |
| Debt To Equity | 225.686 |
| Display Name | Precigen |
| Dividend Yield | 0.0 |
| Earnings Call Timestamp End | 1,785,875,400 |
| Earnings Call Timestamp Start | 1,785,875,400 |
| Earnings Timestamp | 1,785,873,600 |
| Earnings Timestamp End | 1,794,513,600 |
| Earnings Timestamp Start | 1,794,513,600 |
| Ebitda | -35,359,000 |
| Ebitda Margins | -0.41251 |
| Enterprise To Ebitda | -77.441 |
| Enterprise To Revenue | 31.945 |
| Enterprise Value | 2,738,240,768 |
| Eps Forward | -0.22 |
| Eps Trailing Twelve Months | -1.04 |
| Esg Populated | 0 |
| Exchange | NMS |
| Exchange Data Delayed By | 15 |
| Exchange Timezone Name | America/New_York |
| Exchange Timezone Short Name | EDT |
| Fifty Day Average | 7.2836 |
| Fifty Day Average Change | 0.101400375 |
| Fifty Day Average Change Percent | 0.013921739 |
| Fifty Two Week Change Percent | 111.89802 |
| Fifty Two Week High | 8.98 |
| Fifty Two Week High Change | -1.5949993 |
| Fifty Two Week High Change Percent | -0.17761686 |
| Fifty Two Week Low | 3.04 |
| Fifty Two Week Low Change | 4.3450003 |
| Fifty Two Week Low Change Percent | 1.4292765 |
| Fifty Two Week Range | 3.04 - 8.98 |
| Financial Currency | USD |
| First Trade Date Milliseconds | 1,375,968,600,000 |
| Float Shares | 194,599,317 |
| Forward Eps | -0.22 |
| Forward P E | -33.568184 |
| Free Cashflow | -100,097,248 |
| Full Exchange Name | NasdaqGS |
| Full Time Employees | 160 |
| Fullday Change | -0.09499979 |
| Fullday Change Percent | -1.2700506 |
| Fullday Price | 7.385 |
| Gmt Off Set Milliseconds | -14,400,000 |
| Governance Epoch Date | 1,790,812,800 |
| Gross Margins | 0.53006 |
| Gross Profits | 45,435,000 |
| Has Pre Post Market Data | 1 |
| Held Percent Insiders | 0.12637 |
| Held Percent Institutions | 0.73036003 |
| Implied Shares Outstanding | 356,510,980 |
| Industry | Biotechnology |
| Industry Disp | Biotechnology |
| Industry Key | biotechnology |
| Is Earnings Date Estimate | 0 |
| Language | en-US |
| Last Fiscal Year End | 1,767,139,200 |
| Long Business Summary | Precigen, Inc.,a discovery and clinical-stage biopharmaceutical company, develops gene and cell therapies using precision technology to target diseases in areas of immuno-oncology, autoimmune disorders, and infectious diseases. The company offers therapeutic platforms consisting of AdenoVerse platform, which utilizes a library of proprietary adenovectors for gene delivery of therapeutic effectors, immunomodulators, and vaccine antigen; and UltraCAR-T to provide chimeric antigen receptor T cell therapies for cancer patients. It also develops programs based on the UltraCAR-T platform, including PRGN-3005 in Phase 1/1b clinical trial to treat advanced ovarian, fallopian tube, or primary peritoneal cancer; PRGN-3006 in Phase 1b trial for patients with relapsed or refractory acute myeloid leukemia and high-risk myelodysplastic syndromes; and PRGN-3007 in Phase 1/1b trial for the treatment of advanced receptor tyrosine kinase-like orphan receptor 1-positive, hematologic, and solid tumors. In addition, the company is developing programs based on the AdenoVerse immunotherapy platform comprising PRGN-2009 in Phase 2 trial for patients with HPV+ solid tumors; and PRGN-2012 in Phase ½ trial to treat recurrent respiratory papillomatosis. Further, it provides UltraPorator, a proprietary electroporation device. The company was formerly known as Intrexon Corporation and changed its name to Precigen, Inc. in February 2020. Precigen, Inc. was founded in 1998 and is headquartered in Germantown, Maryland. |
| Long Name | Precigen, Inc. |
| Market | us_market |
| Market Cap | 2,632,833,536 |
| Market State | REGULAR |
| Max Age | 86,400 |
| Message Board Id | finmb_22365961 |
| Most Recent Quarter | 1,782,777,600 |
| Net Income To Common | -336,704,992 |
| Next Fiscal Year End | 1,798,675,200 |
| Non Diluted Market Cap | 2,660,201,885 |
| Number Of Analyst Opinions | 3 |
| Open | 7.48 |
| Operating Cashflow | -114,165,000 |
| Operating Margins | 0.41184 |
| Overall Risk | 5 |
| Payout Ratio | 0.0 |
| Phone | 301 556 9900 |
| Previous Close | 7.48 |
| Price Hint | 2 |
| Price To Book | 60.532787 |
| Price To Sales Trailing12 Months | 30.715418 |
| Profit Margins | -1.83983 |
| Quick Ratio | 3.756 |
| Quote Source Name | Nasdaq Real Time Price |
| Quote Type | EQUITY |
| Recommendation Key | none |
| Region | US |
| Regular Market Change | -0.09499979 |
| Regular Market Change Percent | -1.2700506 |
| Regular Market Day High | 7.695 |
| Regular Market Day Low | 7.3802 |
| Regular Market Day Range | 7.3802 - 7.695 |
| Regular Market Open | 7.48 |
| Regular Market Previous Close | 7.48 |
| Regular Market Price | 7.385 |
| Regular Market Time | 1,792,005,418 |
| Regular Market Volume | 2,913,486 |
| Return On Assets | -0.18139 |
| Return On Equity | -8.37075 |
| Revenue Growth | 63.227 |
| Revenue Per Share | 0.25 |
| Sand P52 Week Change | 0.17004645 |
| Sector | Healthcare |
| Sector Disp | Healthcare |
| Sector Key | healthcare |
| Share Holder Rights Risk | 3 |
| Shares Outstanding | 356,510,980 |
| Shares Percent Shares Out | 0.1328 |
| Shares Short | 47,547,517 |
| Shares Short Previous Month Date | 1,788,134,400 |
| Shares Short Prior Month | 42,180,337 |
| Short Name | Precigen, Inc. |
| Short Percent Of Float | 0.24360001 |
| Short Ratio | 10.24 |
| Source Interval | 15 |
| State | MD |
| Symbol | PGEN |
| Target High Price | 17.95 |
| Target Low Price | 11.0 |
| Target Mean Price | 13.65 |
| Target Median Price | 12.0 |
| Total Cash | 38,208,000 |
| Total Cash Per Share | 0.107 |
| Total Debt | 98,345,000 |
| Total Revenue | 85,717,000 |
| Tradeable | 0 |
| Trailing Annual Dividend Rate | 0.0 |
| Trailing Annual Dividend Yield | 0.0 |
| Trailing Eps | -1.04 |
| Trailing Peg Ratio | None |
| Triggerable | 1 |
| Two Hundred Day Average | 5.12635 |
| Two Hundred Day Average Change | 2.2586503 |
| Two Hundred Day Average Change Percent | 0.4405962 |
| Type Disp | Equity |
| Volume | 2,913,486 |
| Website | https://precigen.com |
| Zip | 20,876 |